利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.038 秒)

    Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis
    2.
    发明授权
    Double transfectants of the MHC genes as cellular vaccines for immuno prevention of tumor metastasis 失效
    MHC基因的双重转染子作为用于免疫预防肿瘤转移的细胞疫苗

    公开(公告)号：US5750102A

    公开(公告)日：1998-05-12

    申请号：US412512

    申请日：1995-03-29

    申请人： Lea Eisenbach ,  Michael Feldman

    发明人： Lea Eisenbach ,  Michael Feldman

    IPC分类号： A61K39/00 ,  A61K39/385 ,  A61K48/00 ,  C07K14/74 ,  C12N20060101 ,  A61K35/12 ,  C12N5/08 ,  C12N15/06 ,  C12N15/09

    CPC分类号： A61K39/0011 ,  C07K14/70539 ,  A61K48/00

    摘要： The present invention relates to anti-tumor vaccines comprising at least one type of tumor cell into each of which at least two genes encoding MHC proteins of different haplotypes have been inserted, or naturally expressed, said genes being expressed in said tumor cells and wherein at least one of said MHC proteins has the same haplotype as a haplotype of the individual to be vaccinated. The invention furthermore relates to a method of treating a patient suffering from a tumorous disease comprising administering a vaccine of the invention and to the use of a vaccine of the invention for the preparation of an anti-tumor vaccine.

    摘要翻译： 本发明涉及抗肿瘤疫苗，其包含至少一种类型的肿瘤细胞，其中至少两种编码不同单元型的MHC蛋白的基因已被插入或天然表达，所述基因在所述肿瘤细胞中表达，并且其中在 所述MHC蛋白质中的至少一种具有与待接种个体的单体型相同的单体型。 本发明还涉及治疗患有肿瘤疾病的患者的方法，其包括施用本发明的疫苗以及使用本发明的疫苗来制备抗肿瘤疫苗。

    Tumor associated antigen peptides and use of same as anti-tumor vaccines
    3.
    发明授权
    Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

    公开(公告)号：US07795224B2

    公开(公告)日：2010-09-14

    申请号：US12326675

    申请日：2008-12-02

    申请人： Lea Eisenbach ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

    发明人： Lea Eisenbach ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

    IPC分类号： A61K38/00

    CPC分类号： C12N9/6445 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/4727 ,  C07K14/705 ,  C12N9/16

    摘要： The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译： 本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。 最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

    Methods and Immunogenic Cell Preparations for Treating Antigen-Associated Diseases
    4.
    发明申请
    Methods and Immunogenic Cell Preparations for Treating Antigen-Associated Diseases 失效
    用于治疗抗原相关疾病的方法和免疫原性细胞制剂

    公开(公告)号：US20100129410A1

    公开(公告)日：2010-05-27

    申请号：US11885871

    申请日：2006-02-21

    申请人： Lea Eisenbach ,  Arthur Machlenkin ,  Adrian Paz ,  Boaz Tirosh ,  Esther Tzehoval

    发明人： Lea Eisenbach ,  Arthur Machlenkin ,  Adrian Paz ,  Boaz Tirosh ,  Esther Tzehoval

    IPC分类号： A61K39/00 ,  C12N13/00 ,  C12N5/08 ,  A61P35/00

    CPC分类号： C12N5/0639 ,  A61K35/15 ,  A61K39/0011 ,  A61K41/0009 ,  A61K41/0023 ,  A61K2039/5154

    摘要： A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and/or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject.

    摘要翻译： 公开了抑制有需要的受试者生长，减少或消除细胞群体的方法。 该方法包括（a）热，机械和/或化学损伤包含至少一种表征细胞群细胞的抗原的抗原携带细胞，附带条件是，抗原携带细胞的化学损伤不主要使用一种 或更多的抗肿瘤剂，从而产生免疫原性细胞; 和（b）在受试者中引入包含免疫原性细胞和添加的抗原呈递细胞的细胞聚集体，由此诱导用于抑制或消除受试者细胞群的生长的免疫应答。

    METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES
    5.
    发明申请
    METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES 有权
    在免疫特异性位点治疗肿瘤的方法

    公开(公告)号：US20100189750A1

    公开(公告)日：2010-07-29

    申请号：US12677543

    申请日：2008-09-11

    申请人： Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

    发明人： Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

    IPC分类号： A61K39/00 ,  A61P35/00

    CPC分类号： A61K39/0011 ,  A61K2039/5152

    摘要： A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

    摘要翻译： 提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。 该方法包括系统地施用受试者的免疫特权部位之外的区域，治疗有效量的受试者肿瘤的天真，活的细胞，肿瘤位于免疫特异位点以产生免疫应答 从而治疗受试者的免疫特异部位的癌症。

    Tumor associated antigen peptides and use of same as anti-tumor vaccines
    8.
    发明授权
    Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

    公开(公告)号：US07960507B2

    公开(公告)日：2011-06-14

    申请号：US12844663

    申请日：2010-07-27

    申请人： Lea Eisenbach ,  Boaz Tirosh ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas ,  Arthur Machlenkin ,  Esther Tzehoval

    发明人： Lea Eisenbach ,  Boaz Tirosh ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas ,  Arthur Machlenkin ,  Esther Tzehoval

    IPC分类号： C07K16/00

    CPC分类号： C12N9/6445 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/4727 ,  C07K14/705 ,  C12N9/16

    摘要： The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译： 本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。 最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

    Methods of treating tumors in immune-privileged sites
    9.
    发明授权
    Methods of treating tumors in immune-privileged sites 有权
    治疗免疫特异部位肿瘤的方法

    公开(公告)号：US08741315B2

    公开(公告)日：2014-06-03

    申请号：US12677543

    申请日：2008-09-11

    申请人： Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

    发明人： Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

    IPC分类号： A61K39/00 ,  A61K35/30

    CPC分类号： A61K39/0011 ,  A61K2039/5152

    摘要： A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

    摘要翻译： 提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。 该方法包括系统地施用受试者的免疫特权部位之外的区域，治疗有效量的受试者肿瘤的天真，活的细胞，肿瘤位于免疫特异位点以产生免疫应答 从而治疗受试者的免疫特异部位的癌症。

    Methods and immunogenic cell preparations for treating antigen-associated diseases
    10.
    发明授权
    Methods and immunogenic cell preparations for treating antigen-associated diseases 失效
    用于治疗抗原相关疾病的方法和免疫原性细胞制剂

    公开(公告)号：US08420078B2

    公开(公告)日：2013-04-16

    申请号：US11885871

    申请日：2006-02-21

    申请人： Lea Eisenbach ,  Arthur Machlenkin ,  Adrian Paz ,  Boaz Tirosh ,  Esther Tzehoval

    发明人： Lea Eisenbach ,  Arthur Machlenkin ,  Adrian Paz ,  Boaz Tirosh ,  Esther Tzehoval

    IPC分类号： A61K35/14

    CPC分类号： C12N5/0639 ,  A61K35/15 ,  A61K39/0011 ,  A61K41/0009 ,  A61K41/0023 ,  A61K2039/5154

    摘要： A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and/or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject.

    摘要翻译： 公开了抑制有需要的受试者生长，减少或消除细胞群体的方法。 该方法包括（a）热，机械和/或化学损伤包含至少一种表征细胞群细胞的抗原的抗原携带细胞，附带条件是，抗原携带细胞的化学损伤不主要使用一种 或更多的抗肿瘤剂，从而产生免疫原性细胞; 和（b）在受试者中引入包含免疫原性细胞和添加的抗原呈递细胞的细胞聚集体，由此诱导用于抑制或消除受试者细胞群的生长的免疫应答。